VA
ADPT icon

Vident Advisory’s Adaptive Biotechnologies ADPT Stock Holding History

Vident Advisory’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-48,016
Closed -$174K – 1411
2024
Q2 		$174K Buy
48,016
+12,529
+35% +$39.8K ﹤0.01% 1313
2024
Q1 		$114K Sell
35,487
-4,667
-12% -$18.1K ﹤0.01% 1282
2023
Q4 		$197K Buy
40,154
+10,771
+37% +$49.1K ﹤0.01% 1220
2023
Q3 		$160K Buy
+29,383
New +$194K 0.01% 1156

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Vident Advisory's ADPT Position: Q3 2024 in Review

Vident Advisory sold out of Adaptive Biotechnologies (ADPT) in Q3 2024, closing a stake of 48,016 shares — an estimated $174K sold.

Vident Advisory first reported a position in ADPT in Q3 2023 and held it in 4 quarters. The position peaked at $197K in Q4 2023. 187 funds tracked by Wall St. Rank hold ADPT as of Q3 2024.

  • Vident Advisory reported no remaining Adaptive Biotechnologies position as of Q3 2024 after selling out during the quarter.
  • Vident Advisory sold 48,016 Adaptive Biotechnologies shares in Q3 2024, an estimated $174K.
  • Vident Advisory first reported a position in Adaptive Biotechnologies in Q3 2023 and held it in 4 quarters.
  • Vident Advisory's Adaptive Biotechnologies position peaked at $197K in Q4 2023.
  • 187 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2024.

Based on Vident Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.